Magnetar Financial LLC Has $3.10 Million Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Magnetar Financial LLC lifted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 139.9% during the second quarter, Holdings Channel.com reports. The firm owned 9,417 shares of the medical instruments supplier’s stock after acquiring an additional 5,491 shares during the quarter. Magnetar Financial LLC’s holdings in West Pharmaceutical Services were worth $3,102,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Fidelis Capital Partners LLC bought a new stake in shares of West Pharmaceutical Services in the 1st quarter valued at about $27,000. Crewe Advisors LLC lifted its holdings in West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 71 shares during the period. Quarry LP grew its holdings in West Pharmaceutical Services by 155.3% during the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after acquiring an additional 59 shares during the period. Hazlett Burt & Watson Inc. bought a new position in shares of West Pharmaceutical Services in the 1st quarter worth about $40,000. Finally, Northwest Investment Counselors LLC bought a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at about $40,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Down 0.5 %

Shares of WST stock opened at $306.73 on Tuesday. West Pharmaceutical Services, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $413.70. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. The stock has a 50 day simple moving average of $303.10 and a two-hundred day simple moving average of $336.80. The company has a market cap of $22.34 billion, a P/E ratio of 40.47, a PEG ratio of 10.58 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. During the same period in the prior year, the company earned $2.11 earnings per share. The firm’s revenue was down 6.9% compared to the same quarter last year. Research analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Charles Witherspoon sold 1,029 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at $443,400. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.53% of the stock is owned by company insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.